SAN FRANCISCO (MedPage Today) -- A combination of two investigational antiviral drugs with different mechanisms of action against hepatitis C virus yielded quick and persistent responses in previous nonresponders without the use of pegylated interferon, a researcher said here.
pegylated interferonAASLD: Oral HCV Combo Yields Rapid Response (CME/CE)MedPage Today Infectious Disease Fri, 11/11/2011 - 12:30
AASLD: New HCV Drug Promising, Cuts Out Interferon (CME/CE)MedPage Today Infectious Disease Tue, 11/08/2011 - 12:45
SAN FRANCISCO (MedPage Today) -- Treatment with an investigational hepatitis C drug allowed investigators to dispense with an old stand-by -- pegylated interferon-alpha. PegIFN-lambda shows superior virological response and improved s...EurekAlert! - Infectious and Emerging Diseases Fri, 04/01/2011 - 22:00
(European Association for the Study of the Liver) Highly exciting new data presented today at the International Liver Congress found Pegylated Interferon-lambda (PegIFN-lambda) shows superior virological response in HCV patients of genotypes 1-4, with improved safety and tolerability, compared to Pegylated Interferon-alpha (PegIFN-alpha-2a), the current standard of care in chronic HCV. AASLD: Treating Before Transplant Cuts HCV Recurrence (CME/CE)MedPage Today Surgery Fri, 11/06/2009 - 08:34
BOSTON (MedPage Today) -- In patients with advanced liver disease related to hepatitis C, a course of pegylated interferon and ribavirin (Rebetol) before liver transplant may help them avoid recurrence of infection, a researcher said here. |
